Promontory Therapeutics Announces Interim Efficacy Requirement Reached on Phase 2 Study of PT-112 Monotherapy in Patients with Recurrent Thymoma
PR Newswire —
Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two responses among first 16 patients evaluated to proceed with stage 2 of efficacy assessment. Recent immuno-profiling findings continue to be consistent with...